JP2013530179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530179A5 JP2013530179A5 JP2013514786A JP2013514786A JP2013530179A5 JP 2013530179 A5 JP2013530179 A5 JP 2013530179A5 JP 2013514786 A JP2013514786 A JP 2013514786A JP 2013514786 A JP2013514786 A JP 2013514786A JP 2013530179 A5 JP2013530179 A5 JP 2013530179A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhc
- och
- compound
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 230000000155 isotopic effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229940125388 beta agonist Drugs 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000011257 definitive treatment Methods 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- MTPVBMVUENFFLL-HXUWFJFHSA-N 1-(2-fluorophenyl)-3-[(3s)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea Chemical compound FC1=CC=CC=C1NC(=O)N[C@@H]1C(=O)NC2=CC=CC=C2C(C=2C=CC=CC=2)=N1 MTPVBMVUENFFLL-HXUWFJFHSA-N 0.000 claims 1
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- -1 beta agonists Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960001469 fluticasone furoate Drugs 0.000 claims 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- AVUUHIYJPTWYNX-UHFFFAOYSA-N n-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]-2-methoxyacetamide Chemical compound C1=NC(NC(=O)COC)=CC(OC=2C3=CC=CC=C3C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=CC(C)=CC=3)=CC=2)=C1 AVUUHIYJPTWYNX-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960002586 roflumilast Drugs 0.000 claims 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical group FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1010193.9A GB201010193D0 (en) | 2010-06-17 | 2010-06-17 | Medicinal use |
| GB1010193.9 | 2010-06-17 | ||
| PCT/GB2010/052066 WO2011070368A1 (en) | 2009-12-11 | 2010-12-10 | Antiviral use of urea compounds |
| GBPCT/GB2010/052066 | 2010-12-10 | ||
| PCT/GB2011/051136 WO2011158039A1 (en) | 2010-06-17 | 2011-06-17 | Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013530179A JP2013530179A (ja) | 2013-07-25 |
| JP2013530179A5 true JP2013530179A5 (enExample) | 2014-07-31 |
Family
ID=42471817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514786A Pending JP2013530179A (ja) | 2010-06-17 | 2011-06-17 | 呼吸器合胞体ウイルス（ｒｓｖ）感染の処置に使用するためのウレイド−ピラゾール誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9079893B2 (enExample) |
| EP (1) | EP2582432B1 (enExample) |
| JP (1) | JP2013530179A (enExample) |
| GB (1) | GB201010193D0 (enExample) |
| WO (1) | WO2011158039A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA019974B1 (ru) | 2007-12-19 | 2014-07-30 | Кансер Рисерч Текнолоджи Лимитед | 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| CN102906090B (zh) | 2010-02-01 | 2015-06-24 | 癌症研究技术有限公司 | 1-(5-叔丁基-2-苯基-2h-吡唑-3-基)-3-[2-氟-4-(1-甲基-2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-7-基氧基)-苯基]-脲和相关化合物及它们在治疗中的应用 |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| PT2763984T (pt) | 2011-10-03 | 2016-07-25 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) * | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| KR102283883B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제 |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| ES2724577T3 (es) * | 2013-07-30 | 2019-09-12 | Janssen Sciences Ireland Unlimited Co | Análogos de piridina-piperazinilo sustituidos como compuestos antivirales de RSV |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| US9447076B2 (en) | 2014-02-14 | 2016-09-20 | Respivert Ltd. | Inhibitor of p38 map kinase |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| EP3017812A1 (en) * | 2014-11-06 | 2016-05-11 | Centre National De La Recherche Scientifique (Cnrs) | N1-Benzyl substituted pyrazoles as antiviral agents directed against respiratory synctical virus (RSV) |
| MA41614A (fr) * | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| CA3015978A1 (en) | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| KR20250084983A (ko) | 2017-03-27 | 2025-06-11 | 하이드로-퀘벡 | 전해질 조성물에서 또는 전극 첨가제로서 사용하기 위한 염 |
| CA3140017A1 (en) | 2019-07-19 | 2021-01-28 | Aurore HICK | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1382044A (zh) * | 1999-09-17 | 2002-11-27 | 史密丝克莱恩比彻姆公司 | 细胞因子抑制性抗炎药在鼻病毒感染中的用途 |
| EP1609789A1 (en) | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| US8299074B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| US9260410B2 (en) | 2010-04-08 | 2016-02-16 | Respivert Ltd. | P38 MAP kinase inhibitors |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
-
2010
- 2010-06-17 GB GBGB1010193.9A patent/GB201010193D0/en not_active Ceased
-
2011
- 2011-06-17 EP EP11728920.7A patent/EP2582432B1/en not_active Not-in-force
- 2011-06-17 US US13/805,552 patent/US9079893B2/en active Active
- 2011-06-17 JP JP2013514786A patent/JP2013530179A/ja active Pending
- 2011-06-17 WO PCT/GB2011/051136 patent/WO2011158039A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530179A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| PH12022550783A1 (en) | Antiviral heterocyclic compounds | |
| JP2017528467A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016509591A5 (enExample) | ||
| JP2014518882A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2010509375A5 (enExample) | ||
| JP2007505931A5 (enExample) | ||
| JP2008530240A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2009532417A5 (enExample) | ||
| JP2015535832A5 (enExample) | ||
| PH12021552201A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| RU2013104401A (ru) | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы | |
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2016531871A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2017537886A5 (enExample) | ||
| JP2018502101A5 (enExample) | ||
| JP2019535723A5 (enExample) |